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Abstract
Rheumatoid arthritis clinical trials are strategically designed to collect the disease
activity score of each patient over multiple clinical visits, meanwhile a patient may
drop out before their intended completion due to various reasons. The dropout termi-
nates the longitudinal data collection on the patients activity score. In the presence
of informative dropout, that is, the dropout depends on latent variables from the
longitudinal process, simply applying a model to analyze the longitudinal outcomes
may lead to biased results because the assumption of random dropout is violated.
In this paper we develop a data driven Bayesian joint model for modeling DAS28
scores and competing risk informative drop out. The motivating example is a clinical
trial of Etanercept and Methotrexate with radiographic Patient Outcomes (TEMPO
Keystone et al., 2009).
Keywords: joint selection models; longitudinal data; patient reported outcomes; random
change-point.
1 Introduction
Rheumatoid arthritis is a chronic inflammatory disease that affects the joints. Disease
activity leads to pain, swelling, and joint damage. The cause of rheumatoid arthritis is
unknown but it is known to be an autoimmune disease. Disease activity score based on 28
joints (DAS28) is a composite score measuring disease activity that integrates measures of
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physical examination (number of tender and swollen joints), erythrocyte sedimentation rate
(a hematology test that is a non-specific measure of inflammation), and patient reported
outcome (patient self reported global health on a visual analogue scale).
DAS28 = 0.56
√
Tender28 + 0.28
√
Swollen28 + 0.70 log(ESR)
+0.014(Patient Global Health on VAS)
DAS28 scores can range from 0.49 to 9.07. A score greater than 5.1 is considered high
disease activity, 3.2-5.1 moderate disease activity, 2.6-3.2 low disease activity, and a score
less than 2.6 is considered to be clinical remission. The goal of treatment is to achieve the
lowest possible level of disease activity and clinical remission if possible. Figure 1 displays
the 28 joints considered in the calculation of DAS28 scores.
Figure 1: Twenty-eight joints con-
sidered in the calculation of DAS28
scores.
Clinical trials are strategically designed to collect
the disease activity score of each patient over multi-
ple clinical visits, meanwhile a patient may drop out
before their intended completion due to various rea-
sons. The dropout terminates the longitudinal data
collection on the patient’s disease activity score. In
the presence of informative dropout (Rubin, 1976;
Little and Rubin, 1987), that is, the dropout de-
pends on latent variables from the longitudinal pro-
cess, simply applying mixed effects models to analyze
longitudinal outcomes may lead to biased results be-
cause the assumption of random dropout is violated
(Laird and Ware, 1982). It would be more appro-
priate to jointly model the DAS28 scores and the
dropout to account for the dependency between the
two processes.
Several methods have been proposed in the lit-
erature for jointly modeling longitudinal and time-
to-event data, as reviewed by Hogan and Laird
(1997); Tsiatis and Davidian (2004); Yu et al. (2004);
Ibrahim et al. (2005); Hanson et al. (2011). Joint
models have been widely used in HIV/AIDS clini-
cal trials, cancer vaccine (immunotherepy) trials and
quality of life studies. References include Schluchter
(1992); Pawitan and Self (1993); De Gruttola and
Tu (1994); Tsiatis et al. (1995); Faucett and Thomas
(1996); Wulfsohn and Tsiatis (1997); Faucett et al.
(1998); Henderson et al. (2000); Wang and Taylor (2001); Xu and Zeger (2001); Law et al.
(2002); Song et al. (2002); Chen et al. (2002, 2004); R Brown and G Ibrahim (2003); Brown
and Ibrahim (2003); Brown et al. (2005); Chi and Ibrahim (2006, 2007); Zhu et al. (2012),
and many others.
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Our approach combines different methodologies to deal with the complexity of the data.
The joint model has two parts: the first is a longitudinal random change point model for
repeated measures DAS28 scores; the second part is a time to event hazard risk log normal
model that models two competing risk events. Both parts are linked through a patient
specific random effect. Similar approaches are described next. Jacqmin-Gadda et al. (2006)
propose a joint model for repeated measurements (cognitive test score) and time to event
(dementia). The part of their model for repeated measures, as ours, assumes a linear trend
before a random change point and, in contrast to ours, assumes a polynomial trend after
it. They assume a lognormal model for the time to event as we do for our competing
risk model. Faucett et al. (2002) apply a similar random effects model for the AIDS trial
along with a time-dependent proportional hazards model for the time to AIDS. In their
random effects longitudinal model they assume, as we do, two linear trends before and after
a random change point. Although, as ours, their model contains a subject-specific random
intercept, in contrast to ours, all subjects have a common transition point. Pauler and
Finkelstein (2002) adopts a similar random effect for the longitudinal PSA trajectories and
Cox proportional hazard model for the progression times. By comparing the data pattern
of people who relapse and who do not, they add a strong constraint to the random effects
model with a new indicator the slope after the transition point has to be greater than the
slope before the transition point. For event-time data, Cox proportional hazards model
with a piecewise exponential model is applied to increase flexibility.
Currently, the most commonly used method for jointly modeling lontidudinal and time-
to-event data are likelihood based joint models. Likelihood based joint models are classified
as either selection models or pattern mixture models (Little, 1995). Selection models fac-
tor the joint distribution through the marginal distribution model of the longitudinal out-
come and the conditional distribution of time-to-event given longitudinal latent variables.
Pattern-mixture models (Glynn et al., 1986; Little, 1993) factor the joint distribution differ-
ently by modeling the longitudinal data stratified by time-to-event (e.g., time-to-dropout)
patterns. Our interest in this paper is towards marginal inference on the longitudinal pro-
files. This is, we are interested in assessing the treatment effects while adjusting for the
imbalanced drop out. For this reason we consider selection models over pattern-mixture
models. We also consider a competing risk survival model for informative dropout because,
in practice, a patient may drop out before their intended completion date due to various
competing risks. Joint analysis of longitudinal measurements and competing risks failure
time data has been studied recently both in terms of frequentist approaches (Elashoff et al.,
2007, 2008) and Bayesian approaches (Huang et al., 2010). Such approaches of joint mod-
eling can make the estimates for the longitudinal marginal profile less biased. Therefore
we can draw more reliable conclusions from clinical trials with longitudinal outcomes.
The motivation comes from a randomized double-blinded clinical Trial of Etanercept
and Methotrexate with radiographic Patient Outcomes (TEMPO, Keystone et al., 2009).
The primary objective of this trial is to evaluate the efficacy and safety of a combina-
tion therapy of methotrexate and etanercept for the treatment of rhuematoid arthritis
versus methotrexate alone and etanercept alone. Methotrexate, a disease-modifying an-
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Table 1: Summary of subject disposition in TEMPO study
Methotrexate Etanercept Combo- Total
alone alone therapy
N=228 N=223 N=231 N=682
Completed study 88 (38.6%) 107 (48.0%) 132 (57.1%) 327 (47.9%)
Discontinued study 140 (61.4%) 116 (52.0%) 99 (42.9%) 355 (52.1%)
due to
adverse event 58 (25.4%) 45 (20.2%) 46 (20%) 149 (21.8%)
inefficacious treatment 42 (18.4%) 39 (17.5%) 13 (5.6%) 94 (13.8%)
administrative decision 9 (4.0%) 13 (5.8%) 19 (8.2%) 41 (6%)
other reasons 31 (13.6%) 19 (8.5%) 21 (9.1%) 71 (10.4%)
tirheumatic drug (DMARD), indirectly inhibits the enzyme adenosine deaminase, resulting
in anti-inflammatory effects. Etanercept, a tumor necrosis factor (TNF) inhibitor, is a large
molecule biologic therapy that acts like a sponge to remove TNF-α molecules from the joints
and blood, thereby reducing disease activity and slowing joint destruction. The two drugs
have different mechanisms of action, therefore it is hypothesized that the combination ther-
apy will be more effective in the treatment of rheumatoid arthritis. In the TEMPO study,
a total of 682 subjects were randomized at a 1:1:1 ratio of methotrexate alone, etanercept
alone or the combo-therapy. At the end of the three year study, approximately 52% of the
subjects dropped out from the study due to the following reasons: inefficacious treatment,
adverse events, administrative decisions, and others (Table 1). Dropout due to inefficacious
treatment was highest in the methotrexate group (18.4%) compared to etanercept (17.5%)
and the combination treatment (5.6%). Dropout due to adverse events was lowest in the
combination treatment (20%) compared to methotrexate (25.4%) and etanercept (20.2%).
The remainder of this paper is organized as follows. Section 2 presents our proposed
Bayesian joint model. In Section 3, we apply the model to the TEMPO study and con-
cluding remarks are provided in Section 4.
2 Bayesian Joint Model
2.1 Model for Longitudinal DAS28 Scores
Let yi = (yi1, . . . , yini) denote the DAS28 scores for subject i where ni is the number of
DAS28 scores collected over time for subject i in the study. Let ti = (ti1, . . . , tini) denote
the corresponding vector of observation times and xi = (xi1, . . . , xim) denote the covariate
vector for subject i.
In the subject level data, we observed a change-point pattern in the DAS28 scores with
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a steep decrease in DAS28 scores after initial treatment followed by stability or a more
gradual change. For this reasons we consider the following random change-point model
log(yij) = ψij + ij
ψij = αi + β1iκi + β1i(tij − κi)− + β2i(tij − κi)+ (1)
where ψij = ψi(tij) is the trajectory function on the log scale for subject i and ij is the
associated random residual error. We modeled yij on the log scale to improve linearity
and to remove the constraint of positive values. The trajectory function on the log scale
corresponds to two straight lines that meet at a random change-point κi. The parameters
αi, β1i, β2i, and κi represent the subject level intercept, slopes before and after the random
change-point respectively. Here we use the notation (tij − κi)− = min{tij − κi, 0} and
(tij − κi)+ = max{tij − κi, 0}. The random residual errors are assumed to be independent
and normally distributed with mean zero and variance σ2.
We use normal prior distributions for the parameters αi, β1i, β2i, and κi.
αi ∼ N(µαi , σ2α), µαi = γα0 + γα1xi1 + . . .+ γαmxim
β1i ∼ N(µβ1i , σ2β1), µβ1i = γβ10 + γβ11xi1 + . . .+ γβ1mxim
β2i ∼ N(µβ2i , σ2β2), µβ2i = γβ20 + γβ21xi1 + . . .+ γβ2mxim
κi ∼ N(µκi , σ2κ), µκi = γκ0 + γκ1xi1 + . . .+ γκmxim
We let the means of the parameters vary for each treatment group by letting xi1, . . . , xim
be dummy variables for treatment. The γ parameters are then coefficients that will rep-
resent treatment effect. In our application, with three treatment groups, m = 2. We
complete the model by placing normal hyper-priors with means of zero and large variances
on the hyperparameters γ, this is N(0, 103). We also choose vague priors for the variances:
σ2, σ2α, σ
2
β1
, σ2β2 , σ
2
κ
iid∼ Inverse gamma(0.01, 0.01). We note that the above model is equiva-
lent to a mixed-effect model where the ”random-effect parameters” are re-parameterized
and centered around the ”fixed-effect parameters”. This hierarchical centering reparam-
eterization technique reduces autocorrelation between consecutive Markov chain Monte
Carlo (MCMC) samples (Gelfand et al., 1995).
2.2 Model for Competing Risk Dropout
Competing risk is defined by Gooley et al. (1999) as the situation where one type of event
precludes the occurrence or alters the probability of occurrence of another event (Pintilie,
2006). We consider the following competing risk model for informative dropout. For
the motiviating example, dropout due to adverse event and dropout due to inefficacious
treatment is considered to be informative. Dropout due to administrative decisions and
other are considered uninformative, that is, dropout is random and does not depend on
disease activity outcome.
Let dik denote the time-to-dropout for subject i due to risk k where k = 1 for adverse
event and k = 2 for inefficacious treatment. Let cik denote the corresponding censoring
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indicators for subject i where cik = 1 if subject i dropped out of the study due to risk
k, 0 otherwise. Because dropout tends to occur in the earlier part of the study, we use a
lognormal survival regression model for dik to allow for a humped-shaped hazard function,
log(dik) ∼ N(θik, ς2k)
θik = ϕk0 + ϕk1xi1 + . . .+ ϕkmxim + ωkνi
Here ϕk0, . . . , ϕkm are the cause-specific effects on dropout, xi1, . . . , xim are the dummy
variables for treatment. The last term, ωkνi, is the component for the joint analysis where
νi is the latent variable (or vector) that, in order to link the longitudinal and dropout
processes, is a function of the parameters in the RHS of (1), and ωk is the coefficient (or
vector of coefficients). See next section for more detail about νi. We use normal hyper-
priors for ϕkj and ωk with means of zero and large variances, say 1000. We also assume a
vague prior for ς2k ∼ Inverse gamma(.01, .01).
3 Application to the TEMPO Study
We coded the joint model described in Section 2 in WinBUGS (Lunn et al., 2000, see
Appendix for code). The covariates in the model are xi1 and xi2 representing the two
dummy variables required for three treatment groups. For example, xi1 = 1 if subject i
received methotrexate alone, 0 otherwise, and xi2 = 1 if subject i received etanercept alone,
0 otherwise. Here, the combo-therapy is the reference group.
For νi, we consider different latent variables described in the literature. In the works of
Faucett and Thomas (1996); Wang and Taylor (2001); Ibrahim et al. (2004), and R Brown
and G Ibrahim (2003), missingness (or dropout) is considered to be associated with out-
come. This is known as an outcome dependent selection model where the estimated trajec-
tory at the time of dropout is used as the latent variable. Wu and Carroll (1988); Wulfsohn
and Tsiatis (1997); Follmann and Wu (1995); Henderson et al. (2000); Guo and Carlin
(2004) considered an alternative approach known as the shared parameter selection model
where the missingness (or dropout) is directly related to a trend over time. In the shared
parameter selection models, the parameters from the trajectory function are used as the
latent variables. We considered the different latent variable(s) in the literature and used a
selection model criterion, Deviance Information Criterion (DIC), to determine which latent
variable(s) to use in the final model. The DIC provides a measure of goodness of fit penal-
ized by the effective number of parameters. The model with the smallest DIC is preferred
(Spiegelhalter et al., 2002).
For each model we ran 10,000 MCMC iterations with two chains, each with different
initial values, retaining every fifth sample. We discarded the first 5,000 iterations as burn-in.
We assessed convergence using standard diagnostic tools, that is, converging and mixing
of the two chains. We also assessed autocorrelation as a function of time-lag. Model 1
sets νi = 0, representing separate analysis where the longitudinal model and the dropout
process are not linked. Model 1 assumes that dropout is not informative of outcome. Model
2 considers dropout is associated with the outcome at the time of dropout, denoted as ψ∗i ,
6
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Table 2: Deviance Information Criterion (DIC) for models fitted to the TEMPO study
data. Model 6 is preferred with the smallest DIC.
Model: Type of Analysis νi DIC
1: Separate analysis 0 781.43
Joint analysis where dropout is related to:
2: disease activity at time of dropout ψ∗i 488.98
3: baseline disease activity αi 790.63
4: initial change in disease activity after treatment β1i 574.10
5: the long-term change in disease activity β2i 406.45
Joint analysis,
6: sharing all parameters from the trajectory αi, β1i, β2i 391.04
νi = ψ
∗
i . Model 3 considers dropout is associated with the disease activity at baseline,
νi = αi. In Model 4, dropout is associated with the initial change in disease activity
prior to the change-point, νi = β1i. In Model 5, dropout is associated with the change
in disease activity following the change-point, νi = β2i. Model 6 shares all parameters
from the trajectory function where νi is now a vector with νi = (αi, β1i, β2i). Convergence
and acceptable autocorrelation was met by all six models. Model 6 is preferred with the
smallest DIC (Table 2).
Visually, Model 6 fits well to the subject-level data (Figure 2). Figure 3 shows the
population-level curves for each treatment group using separate analysis (Model 1) versus
joint analysis (Model 6). One would conclude that subjects exposed to the combo-therapy
are more likely to reach clinical remission earlier (DAS28 score < 2.6). However, Model
1 tends to overestimate treatment effectiveness in the methotrexate group (MTX) where
dropout due to inefficacy was the highest 18.4% compared to 17.5% in the etanercept group
(ETAN) and 5.6% in the combo-therapy (MTXETAN).
7
Hennessey et.al.
(a) Patient completed study (b) Patient dropped out due to AE
(c) Patient dropped out due to (d) Patient dropped out due to
inefficacious treatment administrative reasons
Figure 2: The fitted Model 6 to four patient level data. The y-axis represents DAS28
scores on the log scale and the x-axis is time in weeks. The vertical dashed lines represent
the patient specific change-point.
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Figure 3: Separate analysis Model 1 (solid lines) versus Joint analysis Model 6 (dashed
lines)
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4 Discussion
Clinical trials are prone to incomplete outcome data due to patient drop. In the presence
of informative dropout and when drop out is differential across the treatment groups, sep-
arate analysis of the longitudinal data may lead to biased results. In the example TEMPO
study, separate analysis tends to overestimate the treatment effect in the methotrexate
group (MTX) where dropout due to inefficacy was the highest 18.4% compared to 17.5%
in the etanercept group (ETAN) and 5.6% in the combo-therapy (MTXETAN). The pro-
posed joint model provides a way to perform longitudinal data analysis while adjusting for
informative dropout with competing risk. Such approach of joint modeling can make the
effect estimates less biased and therefore we can draw more reliable conclusions from the
clinical trial. In the case where the proportion of dropout is small and there is no associ-
ation between dropout and patient outcome, the joint model analysis should give similar
results to the separate model analysis.
In this paper, we also considered a linear regression random-change point model for the
longitudinal DAS28 scores to account for the observed change-point pattern in the DAS28
scores with a steep decrease in DAS28 scores after initial treatment followed by stability or
a more gradual change. The complexity of the model is easily handled under a Bayesian
framework. The time to run the model is within minutes and convergence was observed
for all parameters. Our proposed Bayesian joint model can also be extended to safety
endpoints where safety endpoints are modeled as a survival process.
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Appendix
WinBUGS code for Model 6: Joint model that shares parameters from the longitudinal
trajectory function
########################################################################
# Data list requires the following:
# N = number of subjects in the study
# n[i] = number of das28 scores observed for subject i
# Y[pointer[i]+j] = vector of log das28 scores. Uses a pointer to identify
# subject i and observation j
# pointer[i] = vector that points to the first observation of subject i in
# the Y vector
# week[pointer[i]+j] = vector of time in weeks for for subject i and das28
# score observation j
# x1[i] = dummy variable that equals 1 if subject i received methotrexate
# alone, 0 otherwise
# x2[i] = dummy variable that equals 1 if subject i received etanercept
# alone, 0 otherwise
# dropoutweek.EFFY[i] = time of dropout due to inefficacious treatment in
# weeks for subject i. Use ’NA’ if subject i is right
# censored
# censored.EFFY[i] = time of right censored in weeks for subject i for
# dropout due to inefficacious treatment. Use ’0’ if
# dropout due to inefficacious treatment was observed
# for subject i
# dropoutweek.AE[i] = time of dropout due to adverse events in weeks for
# subject i. Use ’NA’ if subject i is right censored
# censored.AE[i] = time of right censored in weeks for subject i for dropout
# due to adverse event. Use ’0’ if dropout due to adverse
# event was observed for subject i
########################################################################
model{
for(i in 1:N){
for(j in 1:n[i]){
######################################################################
# Longitudinal process with two lines that meet at a random
#change point
######################################################################
Y[pointer[i]+j]~dnorm(y.star[pointer[i]+j],tau.y)
y.star[pointer[i]+j]<-alpha[i]+beta[i,J[pointer[i]+j]]*
(week[pointer[i]+j]-change.point[i])
J[pointer[i]+j]<-1+step(week[pointer[i]+j]-change.point[i])
}
# reparameterization so that alpha.baseline represents baseline score
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alpha[i]<-alpha.baseline[i]+beta[i,1]*(change.point[i])
######################################################################
# Competing risk for informative dropout where dropout times are
# bounded by censoring times and linked to the longitudinal process by
# sharing parameters from the longitudinal trajectory
######################################################################
dropoutweek.EFFY[i]~dnorm(theta.EFFY[i],
tau.EFFY[trtgrp[i]])I(censored.EFFY[i],)
theta.EFFY[i]<-phi.EFFY[1]+phi.EFFY[2]*x1[i]+phi.EFFY[3]*x2[i]+
omega.EFFY[1]*alpha.baseline[i]+omega.EFFY[2]*beta[i,1]+
omega.EFFY[3]*beta[i,2]
dropoutweek.AE[i]~dnorm(theta.AE[i],
tau.AE[trtgrp[i]])I(censored.AE[i],)
theta.AE[i]<-phi.AE[1]+phi.AE[2]*x1[i]+phi.AE[3]*x2[i]+
omega.AE[1]*alpha.baseline[i]+omega.AE[2]*beta[i,1]+
omega.AE[3]*beta[i,2]
trtgrp[i]<-1+step(x1[i]-0.5)+2*step(x2[i]-0.5)
}
########################################################################
# Priors for the parameters in the longitudinal and the dropout process
########################################################################
for(i in 1:N){
change.point[i]~dnorm(mu.changepoint[i], tau.changepoint)
mu.changepoint[i]<-gamma.chgpt[1]+gamma.chgpt[2]*x1[i]+
gamma.chgpt[3]*x2[i]
}
for(i in 1:N){
alpha.baseline[i]~dnorm(mu.alpha[i],tau.alpha)
mu.alpha[i]<-gamma.alpha[1]+gamma.alpha[2]*x1[i]+
gamma.alpha[3]*x2[i]
}
for(i in 1:N){
for(m in 1:2){
# beta[i,1] and beta2[i,2] represent slopes
#before and after change point
beta[i,m]~dnorm(mu.beta[i,m],tau.beta[m])
mu.beta[i,m]<-gamma.beta[1,m]+gamma.beta[2,m]*x1[i]+
gamma.beta[3,m]*x2[i]
}
}
########################################################################
# Hyper-priors (treatment effect parameters)
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########################################################################
for(trt in 1:3){
gamma.alpha[trt]~dnorm(0,0.001)
for(m in 1:2){
gamma.beta[trt,m]~dnorm(0,0.001)
}
gamma.chgpt[trt]~dnorm(12, 0.01)
phi.EFFY[trt]~dnorm(0,0.001)
phi.AE[trt]~dnorm(0,0.001)
}
#######################################################################
# Component for the joint analysis
# omega.k[1]= coefficient of association between dropout and
# baseline das28 scores
# omega.k[2] = coefficient of association between dropout and
# change in das28 scores before change point
# omega.k[3] = coefficient of association between dropout and
# change in das28 scores after change point
#######################################################################
for(v in 1:3){
omega.EFFY[v]~dnorm(0,0.001)
omega.AE[v]~dnorm(0,0.001)
}
#######################################################################
# Variance (precision) parameters
## ####################################################################
tau.changepoint~dgamma(0.01, 0.01)
tau.y~dgamma(0.01,0.01)
tau.alpha~dgamma(0.01,0.01)
tau.beta[1]~dgamma(0.01,0.01)
tau.beta[2]~dgamma(0.01,0.01)
for(grp in 1:3){
tau.EFFY[grp]~dgamma(0.01,0.01)
tau.AE[grp]~dgamma(0.01,0.01)
}
}
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